fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Cephalexin monohydrate

All products: general benefit

Lupin-Cephalexin · DIN 02471140 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Lupin-Cephalexin · DIN 02471140 Manufacturer: Lupin Pharma Canada Limited; listing date 2025-12-30 Daily cost (source): $0.3464 Health Canada: Marketed since 2025-09-26 · brand LUPIN-CEPHALEXIN · ATC J01DB01 CEFALEXIN · form Tablet · route Oral · ingredients CEPHALEXIN (CEPHALEXIN MONOHYDRATE) 250 MG · company Lupin pharma canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Lupin-Cephalexin: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0866). What the ministry pays, not the patient.

Ministry pays: $0.0866 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02471140)

Source record
DIN 02471140: Lupin-Cephalexin Raw flags: sec3=Y Item: 081228034; group id 43; item number 0098; lccId None; manufacturer id LUP Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.0866; ministry $0.0866 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471140 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96025
Interchangeable products
Apo-Cephalex · DIN 00768723 · $0.0866 Auro-Cephalexin · DIN 02470578 · $0.0866 Cephalexin · DIN 02521253 · $0.0866 Jamp Cephalexin · DIN 02494698 · $0.0866 Keflex · DIN 00403628 · not recorded Teva-Cephalexin · DIN 00583413 · $0.0866
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471140
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J01D, J01DB): coverage varies; not interchangeable

  • Cefadroxil (Duricef): general benefit, not a benefit
  • Cefazolin (Cefazolin for Injection): not a benefit
  • Cefixime (Suprax): general benefit
  • Cefprozil (Ran-Cefprozil): general benefit, not a benefit
  • Ceftriaxone (Rocephin): general benefit, not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CLINDAMYCIN HCL

· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS TEVA-CEPHALEXIN may be indicated for the treatment of bacterial infections of the respiratory tract (1,12)(l3,l4), including otitis media (1,2) , genitourinary tract (3), bone and joints (4,5), skin and soft tissue (6,7), when the infection is caused by susceptible organisms. Culture and susceptibility studies should be performed. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEVA- CEPHALEXIN and other antibacterial drugs, TEVA-CEPHALEXIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 2 https://pdf.hres.ca/dpd_pm/00057614.PDF PM date: August 12, 2020 Source product: TEVA-CEPHALEXIN; DIN 00342084; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.